Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. METHODS: The assessments were integrated in two Phase III trials, ZOE-5...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gerontol A Biol Sci Med Sci
Autors principals: Curran, Desmond, Oostvogels, Lidia, Heineman, Thomas, Matthews, Sean, McElhaney, Janet, McNeil, Shelly, Diez-Domingo, Javier, Lal, Himal, Andrews, Charles, Athan, Eugene, Berglund, Johan, Campora, Laura, de Looze, Ferdinandus, Korhonen, Tiina, Leung, Edward, Levin, Myron, Volpi, Antonio, Johnson, Robert W
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
The Journal of Gerontology: Translational Section
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625590/
https://ncbi.nlm.nih.gov/pubmed/29955836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gerona/gly150
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars